Drug intelligence / Profile preview

HR071603

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Intranasal

Overview

HR071603 is a nasal spray formulation of R-ketamine (arketamine), the R(-)-enantiomer of ketamine. It functions as an NMDA antagonist and glutamate receptor modulator. Developed by Jiangsu HengRui Medicine Co., Ltd., it is being investigated for its potential rapid and sustained antidepressant effects, particularly in treatment-resistant depression, with a favorable safety profile.

Other names: R-氯胺酮Hydrochloric Acid (R) -Ketamine Nasal Spray

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on HR071603.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HR071603.

Explore the full profile